Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
FDA approves Roche's PATHWAY HER2 test for biliary tract cancer
FDA approves Roche’s PATHWAY anti-HER2/neu (4B5) test for biliary tract cancer, identifying patients eligible for targeted therapy ZIIHERA, potentially improving clinical outcomes.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
ADCs combine monoclonal antibody precision with cytotoxic drugs, improving efficacy and safety. They selectively target cancer cells, reducing side effects and treating advanced or drug-resistant cancers. ADC technology is advancing with enhanced linker stability, optimized payloads, and the bystander effect, expanding the scope of targetable cancers. Challenges include off-target toxicity, dose optimization, and biomarker identification. ADCs offer potential for personalized oncology therapies, with 15 FDA-approved ADCs as of 2024. Future advancements aim to improve therapeutic indices, reduce toxicity, and enhance combination therapies.
China's National Reimbursement Drug List (NRDL) outlook for 2024
The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.
FDA Expands Labelling for Roche's Pathway Rabbit Monoclonal Primary Antibody in ...
The FDA approved Roche’s Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, the first companion diagnostic for HER2-positive biliary tract cancer (BTC) patients eligible for treatment with Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii). This marks the first FDA-approved treatment for previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC. The test aims to improve clinical outcomes for BTC patients by providing timely, clear, and reliable results for therapeutic decisions.
Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in
The 2024 NCCN Breast Cancer guidelines update includes ribociclib plus an aromatase inhibitor as a preferred regimen for HR-positive, HER2-negative early breast cancer. Ribociclib is the only category 1 CDK4/6 inhibitor for first-line treatment in combination with an AI. The guidelines also add adjuvant ribociclib for premenopausal patients with HR-positive, HER2-negative disease, and revise other treatment pathways. The FDA approval of adjuvant ribociclib may apply to a wider population than abemaciclib, with ribociclib given at 400 mg for 3 years, compared to abemaciclib's 2 years.
Related Clinical Trials:
Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer
HER2-targeted therapy is standard for stage II/III HER2-positive breast cancer, with options like trastuzumab and pertuzumab delivered IV or subcutaneously. Clinical trials explore de-escalation or escalation of therapy based on patient and disease characteristics, with pivotal studies like NeoSphere, TRYPHAENA, FeDeriCa, PHranceSCa, and KATHERINE informing treatment paradigms. T-DM1 is standard for residual disease post-neoadjuvant therapy.
Related Clinical Trials:
Jazz gets first FDA nod for HER2 bispecific Ziihera
Jazz Pharmaceuticals' HER2-directed bispecific antibody Ziihera gains FDA approval for biliary tract cancer (BTC), with potential for broader indications like HER2-positive breast and gastric cancers. The approval is based on a 52% objective response rate in the HERIZON-BTC-01 trial, with Jazz aiming for peak sales of $2 billion. The company is also conducting phase 3 trials in gastroesophageal adenocarcinoma and breast cancer.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
2024 NCCN guidelines for melanoma emphasize neoadjuvant therapy and TIL therapy with lifileucel. Neoadjuvant therapy is now preferred for stage III or IV resectable disease, with options like nivolumab/ipilimumab and pembrolizumab. Lifileucel, a TIL therapy, is a major advancement for refractory cases, requiring specialized administration. Multidisciplinary communication is crucial for implementing these changes.
Related Clinical Trials:
FDA approves biliary tract cancer treatment from Jazz
FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab), the first dual HER2-targeted bispecific antibody for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, administered every two weeks.
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma
David H. Aggen, MD, PhD, discusses the challenge of personalizing frontline treatment for urothelial cancer patients living over 2 years, highlighting the FDA approvals of enfortumab vedotin-ejfv plus pembrolizumab and nivolumab plus cisplatin and gemcitabine. Aggen emphasizes the need for biomarker research to guide treatment selection and mitigate toxicity, noting the potential use of circulating tumor DNA (ctDNA) to tailor therapy.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath